Advertisement

Future Developments in Adjuvant and Palliative Systemic Endocrine Therapies

Conference paper
  • 10 Downloads

Abstract

The World Overview of adjuvant trials for early breast cancer published in the Lancet in January 1992 (Early Breast Cancer Trialists’ Collaborative Group 1992) provided us with secure data to allow the rational employment of adjuvant systemic chemotherapy and endocrine therapy. The World Overview also set the agenda for the next decade of clinical trials in the management of early breast cancer. A whole raft of new questions has been defined concerning the role of endocrine manipulation in both pre- and post-menopausal women.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Badwe RA, Gregory WM, Cahudary MA et al (1994) Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1: 1261–1264Google Scholar
  2. Benson JR, Wakefield LM, Sporn MB et al (1993) Secretion of TGFß isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen (Abstr). Breast Cancer Res Treat 27: (1/2): 163Google Scholar
  3. Butta A, Maclennan K, Flanders KC, Sacks NPM, Smith I, Mackinna A, Dow-sett M, Wakefield LM, Sporn MB, Colletta AA (1992) Induction of transforming growth factor beta1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261–4264PubMedGoogle Scholar
  4. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC (1991) Pyrrolidino-4-iodotamoxifen and 4-Iodotamoxifen. New analogues of the antiestrogen Tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851–5955PubMedGoogle Scholar
  5. Colletta AA, Benson JR, Baum M (1994) Alternate mechanisms of action of antioestrogens. Breast Cancer Res Treatment 31: 5–9CrossRefGoogle Scholar
  6. Cullen KJ, Lippmann ME, Chow D, Hill S, Rosen N, Zwiebel JA (1992) Insulinlike growth factor-II over-expression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol (Oxf) 6: 91–100CrossRefGoogle Scholar
  7. DeFriend D, Blarney RE, Robertson JF, Walton P, Howell A (1993) Response to the pure anti-oestrogen ICI 182,780 after Tamoxifen failure in advanced breast cancer (Abst). Breast Cancer Res Treat 27 (1/2): 136Google Scholar
  8. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: (8784): 1–15;Google Scholar
  9. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339 (8785): 71–85Google Scholar
  10. Fentiman IS, Gregory WM (1994) Peri-operative hormones and prognosis in breast cancer. Eur J Cancer 30A (12): 1892–1894PubMedCrossRefGoogle Scholar
  11. Fisher B, Gunduz N, Coyle J (1989) Presence of a growth-stimulating factor in serum following primary tumour removal in mice. Cancer Res 49:1996–2001PubMedGoogle Scholar
  12. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1; 1: pp 27, 1995CrossRefGoogle Scholar
  13. Folkman J: Tumor angiogenesis. In: Mendelsohn J, Howley P, Liotta L, Israel M, eds. The Molecular Basis of Cancer, W B Saunders Company, Philadelphia, in press (1994)Google Scholar
  14. Folkman J: What is the evidence that tumours are angiogenesis dependent? JNCI 82: 4–6, 1990PubMedGoogle Scholar
  15. Folkman J: What is the evidence that tumours are angiogenesis dependent? JNCI 82: 4–6, 1990.PubMedGoogle Scholar
  16. Gagliardi A, Collins DC (1993) Inhibition of angiogenesis by anti-oestrogens. Cancer Res 53: 533–535PubMedGoogle Scholar
  17. Horak E, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. The Lancet 340: 1120–1124, 1992CrossRefGoogle Scholar
  18. Hori A, Sasada R, Matsutani E et al: Suppression of solid tumour growth by immuno-neutralising monoclonal antibody against fibroblasts growth factor. Cancer Res 51: 6180–6184, 1991PubMedGoogle Scholar
  19. Huynh HT, Tetenes E, Wallace L, Pollack M (1993) In vivo inhibition of Insulinlike growth factor I gene expression by tamoxifen. Cancer Res 53:1727–1730PubMedGoogle Scholar
  20. Jordan VC (ed) (1994) Long-term Tamoxifen therapy for breast cancer. University of Wisconsin Press, MadisonGoogle Scholar
  21. Jordan VC, Morrow M (1994) Should clinicians be concerned about the carcinogenic potential of Tamoxifen? Eur J Cancer 30 (11): 1714–1721CrossRefGoogle Scholar
  22. Lippman ME. New Approaches in Diagnosing and Treating Breast Cancer Conference organised by Cambridge Healthtech Institute. Philadelphia November 1994Google Scholar
  23. Myall Y, Shiu RPC, Bhaumick, B, (1984) Receptor binding and growth promoting activity of insulin-like growth factors in human breast cancer cells (T47D) in culture. Cancer Res 44: 5486–5490Google Scholar
  24. Nicholson RI, Walker KJ, Turkes A et al (1985) Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J Steroid Biochem 23: 843–847PubMedCrossRefGoogle Scholar
  25. Nolvadex Adjuvant Trial Organisation (1987) Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 54: 608–611Google Scholar
  26. Shultz GS and Grant MB: Neovascular growth factors. Eye (London) 5: 178–180, 1991Google Scholar
  27. Steinberg KK, Thacker SB et al (1991) Meta-analysis of the effect of oestrogen replacement therapy on risk of breast cancer. JAMA 265: 1985–1990PubMedCrossRefGoogle Scholar
  28. Tabar L, Fagerberg G, Hsiu-Hsi Chen et al (1995) Efficacy of breast cancer screening by age. New results from the Swedish two-country trial. Cancer 75 (10): 2507–2517PubMedCrossRefGoogle Scholar
  29. Tripathy D (1994) How long should adjuvant Tamoxifen be continued? Oncology 8 (10): 25–30PubMedGoogle Scholar
  30. Wakeling AE, Dukes M. Bowler J (1991) A potent specific pure anti-oestrogen with clinical potential. Cancer Res 51: 3867–3873PubMedGoogle Scholar
  31. Weidner N, Semple JP, Welch WR and Folkman J: Tumour angiogenesis and metastasis — correlation in invasive breast carcinoma. NEJM 324: 1–8 1991PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • M. Baum

There are no affiliations available

Personalised recommendations